Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

This study tests an experimental drug called TQB2102 for people with advanced non-small cell lung cancer that has a HER2 gene abnormality. The drug is designed to deliver a strong cancer-killing agent directly to tumor cells while sparing healthy tissue. About 270 adults aged 18-…

This study tests an experimental drug called TQB2102 in about 102 people with HER2-positive advanced or metastatic biliary tract cancer that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants must…

This early-phase study tests a new drug called TQB6411 in 216 adults with advanced cancers that have not responded to other treatments. The drug is designed to attach to specific markers on cancer cells and deliver a toxin to kill them. The main goals are to find the safest dose …

This study tests whether a new drug called TQB2102 works better than the usual treatment (TCbHP) for people with HER2-positive breast cancer before they have surgery. About 544 participants will be randomly assigned to one of the two treatments. The main goal is to see if the can…

This study tests a new drug called TQB2930 combined with chemotherapy against the standard drug trastuzumab with chemotherapy. It is for people with advanced HER2-positive breast cancer who have already tried at least two other anti-HER2 treatments. The goal is to see if the new …